This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA grants priority review to prostate cancer drug, Q&A on annual breast cancer screenings among childhood cancer survivors
Among the top stories in hematology/oncology last week were the FDA granting priority review to enzalutamide for the treatment of men with metastatic hormone-sensitive prostate cancer, and a Q&A centering on a study that suggested annual breast cancer screenings may prevent more than half of all breast cancer-related deaths among childhood cancer survivors.
Other highlights included a study showing that exercise may help patients with metastatic colorectal cancer achieve longer progression free survival, clinical trial results that suggested dual CAR T-cell combination may be an effective treatment option for multiple myeloma, and research that found survivors of most types of cancers demonstrated increased medium- to long-term risk for at least one cardiovascular disease compared with the general population.
FDA grants priority review to Xtandi for metastatic hormone-sensitive prostate cancer
The FDA has granted priority review to enzalutamide for the treatment of men with metastatic hormone-sensitive prostate cancer, according to the drug’s manufacturer. Read more.
Q&A: Annual screening may reduce breast cancer deaths by half among childhood cancer survivors
Initiating annual breast cancer screening at a younger age may prevent more than half of all breast cancer-related deaths among childhood cancer survivors treated with chest radiation, according to results of a comparative modeling study presented at this year’s ASCO Annual Meeting. Read more.
Exercise linked to longer progression free survival, fewer treatment-related toxicities in metastatic colorectal cancer
Patients with metastatic colorectal cancer who exercised regularly achieved longer progression free survival than those who did not, according to results of a study published in the Journal of Clinical Oncology. Read more.
Dual CAR T-cell combination a ‘promising treatment option’ for multiple myeloma
A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with relapsed or refractory multiple myeloma, according to results of a single-center, single-arm phase 2 clinical trial published in The Lancet Haematology. Read more.
Cancer survivors at higher medium-, long-term risk for cardiovascular disease
Survivors of most types of cancers demonstrated increased medium- to long-term risk for at least one cardiovascular disease compared with the general population, according to results of a retrospective study published in The Lancet. Read more.